|
Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance.
J Thromb Haemost. 2003 Dic; 1(12):2531-5.
Antovic A, Blomback M, Bremme K, Van Rooijen M, He S. |
|
Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis.
Thromb Haemost. 2003 Dic; 90(6):1187-91.
Lau HK, Segev A, Hegele RA, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH. |
|
Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis.
Thromb Haemost. 2003 Dic; 90(6):1061-4.
Barcellona D, Fenu L, Cauli C, Pisu G, Marongiu F. |
|
A monoclonal antibody to the fibrinogen gamma-chain alters fibrin clot structure and its properties by producing short, thin fibers arranged in bundles.
J Thromb Haemost. 2003 Dic; 1(12):2594-602.
Scheiner T, Jirouskova M, Nagaswami C, Coller BS, Weisel JW. |
|
High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy.
Thromb Haemost. 2003 Dic; 90(6):1163-72.
Vene N, Mavri A, Kosmelj K, Stegnar M |
|
Soluble uPAR inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling.
J Biol Chem.. 2003 Nov; 278(47):46692-8. Epub 2003 Sep 8
Jo M, Thomas KS, Wu L, Gonias SL. |
|
Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions.
EMBO J. 2003 Nov; 22(22):5994-6003.
Cunningham O, Andolfo A, Santovito ML, Iuzzolino L, Blasi F, Sidenius N. |
|
Enhanced Thrombosis in Atherosclerosis-Prone Mice Is Associated With Increased Arterial Expression of Plasminogen Activator Inhibitor-1.
Arterioscler Thromb Vasc Biol. 2003 Nov; 23(11):2097-103. Epub 2003 Sep 25
Schafer K, Muller K, Hecke A, Mounier E, Goebel J, Loskutoff DJ, Konstantinides S. |
|
Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders.
Eur J Haematol. 2003 Nov; 71(5):377-84.
Jensen MK, Holten-Andersen MN, Riisbro R, de Nully Brown P, Larsen MB, Kjeldsen L, Heickendorff L, Brunner N, Hasselbalch HC |
|
Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux.
J Thromb Haemost. 2003 Nov; 1(11):2368-73.
Lisman T, Bijsterveld NR, Adelmeijer J, Meijers JC, Levi M, Nieuwenhuis HK, De Groot PG. |
|
Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.
Stroke. 2003 Oct; 34(10):2387-91. Epub 2003 Ago 28
Santamaria A, Oliver A, Borrell M, Mateo J, Belvis R, Marti-Fabregas J, Ortin R, Tirado I, Souto JC, Fontcuberta J |
|
Vitamin C affects thrombosis/ fibrinolysis system and reactive hyperemia in patients with type 2 diabetes and coronary artery disease.
Diabetes Care. 2003 Oct; 26(10):2749-53.
Tousoulis D, Antoniades C, Tountas C, Bosinakou E, Kotsopoulou M, Toutouzas P, Stefanadis C. |
|
Genetic deletion of tissue-type plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosis.
Thromb Haemost. 2003 Oct; 90(4):710-6.
Rezaee F, Gijbels M, Offerman E, Verheijen J. |
|
Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor.
Blood Coagul Fibrinolysis. 2003 Sep; 14(6):557-62.
Lisman T, Adelmeijer J, Nieuwenhuis HK, de Groot PG |
|
Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
Br J Haematol. 2003 Sep; 122(6):958-65.
Zorio E, Castello R, Falco C, Espana F, Osa A, Almenar L, Aznar J, Estelles A. |
|
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients.
Thromb Haemost. 2003 Sep; 90(3):538-48.
Look M, van Putten W, Duffy M, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Fred Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendah PO, Quillien V, Daver A, Ricolleau |
|
Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women.
J Thromb Haemost. 2003 Sep; 1(9):1984-91.
Madsen JS, Kristensen SR, Gram J, Bladbjerg EM, Henriksen FL, Gram J, Christensen K, Jespersen J. |
|
Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
Thromb Haemost. 2003 Jul; 90(1):92-100.
Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP |
|
Identification of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in human platelets.
Blood. 2003 Jun; 101(12):4844-6. Epub 2003 Feb 20
Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JC, Bouma BN |
|
Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure.
Stroke. 2003 Jun; 34(6):E48-50. Epub 2003 May 15
Heo JH, Kim SH, Lee KY, Kim EH, Chu CK, Nam JM. |
